Topic
Evidence Critique
Where the popular health-science narrative breaks. Keto trials and their retractions, the LMHR hypothesis, supplement marketing, and the difference between mechanism and outcome data.
6 articles
I Was Ready to Pay to Watch My Plaque Shrink. Then I Learned the Number Moves on Its Own.
AI plaque analysis from Cleerly and HeartFlow measures arteries to the cubic millimeter. Rescan an hour later and the number moves. Read before you pay for one.
Aging's Zombie Cells Have an Inflammatory Fuel Line. Mayo Just Found the Valve.
A Mayo-led Nature study shows how mitochondrial metabolism opens inflammatory genes in senescent cells, tying several hallmarks of aging into one circuit behind inflammation.
The Longevity Compound Promoted on Half a Mechanism
Its entire case for your heart is one biochemical arrow. I followed the other one, the one that runs the wrong way, and as a guy with a stent I walked away.
The Gut May Be the Point: Metformin, Citrulline, and the Exercise Question
A new Nature Metabolism paper places metformin's main effect in the gut, not muscle. That eases one exercise-blunting fear and raises a sharper one: citrulline and nitric oxide.
I Was “Metabolically Healthy.” I Got a Stent at 44 Anyway.
Low hsCRP, a flat CGM, no insulin resistance: every marker the low-carb world calls “safe.” Then a CT angiogram found an 80% blockage in my right coronary artery.
The Study the Keto Community Uses to Say LDL Doesn’t Matter. Then the Follow-Up Got Retracted.
A keto study is cited to argue high LDL is harmless when metabolic markers are clean. The follow-up that measured soft plaque was retracted in 2026. Here's what the evidence shows.